How to Invest in Biotech

Last updated June 2026

Short answer

Biotech is one of the higher-upside and higher-risk themes in the market, driven by real innovation like GLP-1 obesity drugs, gene editing, and AI-assisted drug discovery. The catch is that it is unusually binary: a single trial result can make or break a clinical-stage company overnight. The main ways to invest are large-cap biopharma (steadier), clinical-stage biotech (speculative), a biotech ETF (diversifies the binary risk), and a thematic basket you build and control. Size it as a satellite position, not a core one. Walnut is an AI investing assistant that can build a biotech basket you approve, framing each holding against the S&P 500, and is not an investment adviser.

Biotech is exciting for a real reason: it is where some of the most consequential innovation of the decade is happening. It is also one of the few corners of the market where a single day can decide a company’s fate. A drug either hits its endpoint in a trial or it does not, and the stock moves accordingly. That binary nature is the single most important thing to understand before you put money in. This guide covers why biotech has become a theme, the honest ways to get exposure (from steadier large-cap names to speculative clinical-stage bets to diversified funds and baskets), the risks that actually matter, how to think about sizing, and where a tool like Walnut fits.

Why biotech is a theme

Biotech has moved from a specialist corner to a mainstream theme because several waves of innovation are landing at once, each with a large addressable market:

GLP-1 obesity and diabetes drugs. The medicines behind much of biotech’s recent attention, with enormous demand and a race to develop next-generation versions. See the GLP-1 obesity drugs theme for the companies involved.
Gene editing and cell therapies. Approaches that were laboratory science a few years ago are now moving into the clinic, opening the door to treatments for conditions that had none.
AI-assisted drug discovery. Machine learning is being used to speed up how candidate drugs are found and tested, potentially shortening the long, expensive path from idea to trial.

These trends are genuine, and that is exactly why biotech attracts thematic interest. But a real theme does not remove company-level risk. The excitement is about a wave; the money is in individual companies whose specific drugs can still fail. Holding the theme and respecting the risk are not in tension; they are the whole job.

The one thing to understand first: biotech is binary

Most sectors move on gradual things: earnings that beat or miss by a little, a slow shift in demand, a change in margins. Biotech, especially at the clinical stage, often moves on all-or-nothing events. A company can spend years and hundreds of millions developing a drug, and its value can rest almost entirely on whether one trial reads out positive and whether regulators approve it.

The practical consequence is that a single clinical-stage stock can multiply on good news or lose most of its value in a day on a failed trial, a safety signal, or a rejection. This is not unusual in biotech; it is the norm. Everything else in this guide, from diversification to position sizing, is a response to that one fact. The way you survive biotech is not by predicting trial outcomes, which nobody can reliably do, but by making sure no single outcome defines your result.

The ways to invest in biotech

There is a spectrum from steadier to more speculative, and the right point on it depends on your risk tolerance and how much you understand the underlying science. Here are the main routes, each described on the same fields.

Large-cap biopharma

The established drugmakers with approved products already generating revenue, deep pipelines, and the balance sheets to fund years of research. They still rise and fall on trial results and patent cliffs, but a single failure rarely threatens the whole company.

Best for: Getting biotech and pharma exposure without betting the position on one clinical readout.
Risk level: Moderate.
The catch: Lower within biotech, not low overall: patent expirations, pricing pressure, pipeline disappointments, and regulatory shifts all still move these names.

Clinical-stage biotech

Younger companies whose value rests on drugs still in trials, often with little or no revenue. The stock can multiply on a positive readout or approval, and can lose most of its value on a failed trial, a safety signal, or a rejection.

Best for: Investors who understand the science and accept that any single name can go to a fraction of its value.
Risk level: Very high.
The catch: Very high and binary: a single trial result, a safety flag, or an FDA decision can cut the stock in half or worse in a day. Concentration here is how people lose most of a position.

Biotech ETFs

Funds that hold a basket of biotech and pharma companies in one ticker, spreading a single position across many names. The winners and losers partly offset each other, so one blown trial does not sink the whole holding.

Best for: Getting broad biotech exposure while diversifying away the single-catalyst, single-company risk.
Risk level: Moderate to high.
The catch: The sector still swings hard as a group, and some funds tilt toward small, speculative names or a few large ones, so read the holdings before assuming it is safe.

Thematic biotech basket

A small set of biotech names you choose around a stated thesis (say, GLP-1 obesity drugs or gene editing), held at target weights you set, so you control exactly which companies and how much of each you own.

Best for: Investors who want a defined thesis and control over the names, rather than a fund’s fixed list.
Risk level: Depends on your weights.
The catch: You carry the concentration you choose: a tight basket of speculative names is nearly as binary as owning them singly, so weighting and position size do the risk work.

A common approach is to blend these rather than pick one: broad exposure through an ETF or a diversified basket as the base, with any individual clinical-stage names kept small and understood. For more on the basket approach, see thematic investing, and for the fund route, the best biotech ETFs.

The risks that actually matter

Biotech carries the usual market risk plus a set that is specific to how the science and regulation work. Before you invest, these are the ones to price in:

Trial failures. The headline risk. A drug that misses its endpoint can wipe out much of a company’s value overnight, and this happens regularly.
Single-catalyst blowups. When one event (a readout, an FDA decision, a safety flag) decides the outcome, there is no gradual warning and little room to react.
Concentration. Owning one or two clinical-stage names magnifies every other risk. The same money spread across many names behaves very differently.
Regulatory and pricing pressure. Approvals can be delayed or denied, and drug pricing is a live political and commercial issue that affects even profitable large-cap names.
Patent cliffs and dilution. Large-cap biopharma faces revenue drops when patents expire, while cash-hungry early-stage companies often raise money by issuing new shares, diluting existing holders.

None of these are reasons to avoid biotech entirely. They are reasons to diversify and to size the position so that any one of them, if it hits, is survivable rather than portfolio-defining.

How to size a biotech position

Because biotech is volatile and binary, it is usually treated as a satellite position, a slice of a diversified portfolio rather than a core holding. This is not advice, but a few principles hold up:

Size to what you could lose, not what you hope to gain. The upside is easy to imagine; the downside is the number that should set the position size.
Smaller for more speculative names. A clinical-stage bet warrants a smaller position than a large-cap biopharma name or a diversified fund, because the range of outcomes is wider.
Diversify within the theme. Spreading across several names, or using an ETF or basket, keeps one failed trial from defining your result.
Decide the size before the excitement. Set your target weight when you are calm, not after a big move, and rebalance back toward it rather than letting a winner or a hope run the position.

At a glance

Way to invest	Best for	Risk level
Large-cap biopharma	Getting biotech and pharma exposure without betting the position on one clinical readout	Moderate
Clinical-stage biotech	Investors who understand the science and accept that any single name can go to a fraction of its value	Very high
Biotech ETFs	Getting broad biotech exposure while diversifying away the single-catalyst, single-company risk	Moderate to high
Thematic biotech basket	Investors who want a defined thesis and control over the names, rather than a fund’s fixed list	Depends on your weights

How Walnut fits in

To be upfront, since this is our site: Walnut is one option among several here, not the only way to invest in biotech, and not a magic fix for its risk. Walnut is the AI investing assistant you chat with on the broker you already own. It connects your existing brokerage through SnapTrade, read-only by default, and lets you talk through a theme like biotech in plain language.

If you want the basket route, Walnut can propose a thematic biotech basket, a set of names at target weights, that you review and approve before anything happens, with each holding framed against the S&P 500 so you can see how it is doing relative to the broad market. Every trade needs your approval, and the concentration and sizing choices stay yours. What Walnut does not do is remove biotech’s binary risk or predict a trial outcome; it helps you research, organize, and act on a thesis you own. Walnut is not an investment adviser.

The bottom line

Biotech is a genuine theme, powered by GLP-1 drugs, gene editing, and AI-assisted discovery, and it can earn a place in a diversified portfolio. But it is unusually binary: single trial readouts can make or break a clinical-stage name overnight, so how you get exposure matters as much as whether you do. Large-cap biopharma is steadier, clinical-stage biotech is speculative, a biotech ETF diversifies the single-company risk, and a thematic basket gives you control at the cost of carrying the concentration you choose. Size it small, diversify within it, and respect the downside. Walnut can help build a biotech basket you approve, framing each holding against the S&P 500, but it is one option, and it is not an investment adviser.

Try Walnut on top of your broker

Walnut connects any major US broker in a few clicks, then lets you talk through a theme like biotech and turn it into a basket you approve, with each holding framed against the S&P 500. Read-only by default; you approve every trade.

Create a free Walnut account

FAQ

How do I invest in biotech?

You have a few honest options. You can buy large-cap biopharma for steadier exposure, buy clinical-stage biotech for speculative upside (and real downside), buy a biotech ETF to diversify the binary risk across many names, or build a thematic basket you control. There is no single right answer; it depends on your risk tolerance and how much you understand the science. Walnut can help build a biotech basket, but it is not an investment adviser.

Is biotech a good investment?

Biotech can offer strong innovation-driven upside, but it is one of the more volatile and binary corners of the market. Clinical-stage names can multiply on a good trial or collapse on a bad one, while large-cap biopharma is steadier but still exposed to patent cliffs and pricing pressure. It can fit a diversified portfolio in a sized position, but it is not a place to concentrate money you cannot afford to lose.

Why is biotech so risky?

Biotech is unusually binary. A company’s value can hinge on a single trial readout or an FDA decision, and the outcome is often close to all-or-nothing: the drug works and gets approved, or it does not. That makes individual clinical-stage stocks capable of huge single-day moves in either direction. Diversifying across many names, through an ETF or a spread-out basket, reduces the chance that one failure defines your result.

What is driving biotech as a theme?

Several innovation waves are converging: GLP-1 obesity and diabetes drugs reaching enormous demand, gene editing and cell therapies moving from lab to clinic, and AI-assisted drug discovery speeding pipelines. These trends are real, but excitement about a theme does not remove the company-level risk that any specific drug can still fail in trials. A theme can be genuine and the individual stocks still binary.

Should I buy individual biotech stocks or an ETF?

It comes down to how much single-company risk you want. Individual clinical-stage stocks offer the biggest upside and the biggest chance of a near-total loss on one bad readout. A biotech ETF spreads that risk across many names, so no single trial defines your result, at the cost of diluting any one winner. Many investors blend the two, or hold a diversified basket, rather than concentrating in one speculative name.

How much of my portfolio should be in biotech?

There is no universal number, and this is not advice, but biotech is usually treated as a satellite position rather than a core holding because of its volatility. Many people size a high-risk theme small enough that a bad outcome is survivable. The more speculative the names (clinical-stage over large-cap), the smaller the position typically is. Match the size to what you could lose, not to the upside you hope for.

What are the biggest risks in biotech investing?

Trial failures are the headline risk: a drug that does not hit its endpoint can wipe out much of a company’s value overnight. Beyond that, there are FDA rejections, safety signals, patent cliffs for large-cap names, pricing and regulatory pressure, dilution from cash-hungry early-stage companies, and single-catalyst blowups where one event decides the outcome. Concentration in one or two names magnifies every one of these.

What is the GLP-1 theme in biotech?

GLP-1 drugs are the obesity and diabetes medicines behind much of biotech’s recent attention, with large addressable demand and several companies racing on next-generation versions. You can read more on the GLP-1 obesity drugs theme page. As with any biotech theme, the trend can be real while individual stocks remain exposed to trial and competitive risk, so diversification and sizing still matter.

Can AI help me invest in biotech?

AI assistants can help you research the theme, understand a company’s pipeline in plain language, and organize names into a basket around a thesis. What they cannot do is remove the binary risk or predict a trial outcome. Walnut is an AI investing assistant that connects your existing brokerage (read-only by default) and can build a biotech basket you approve, framing each holding against the S&P 500. It is not an investment adviser.

How does Walnut help with biotech investing?

Walnut is the AI investing assistant you chat with on the broker you already own. You can talk through a biotech thesis, and it can propose a thematic basket of names at target weights that you review and approve before anything happens, with each holding framed against the S&P 500. It connects through SnapTrade read-only by default and requires your approval for any trade. Walnut is not an investment adviser, and the concentration and sizing choices are yours.

Is biotech investing suitable for beginners?

Broad, diversified exposure through a biotech ETF or a spread-out basket is far more beginner-appropriate than picking individual clinical-stage names, which really require understanding the science and the trial calendar. Whatever the route, a small, sized position matters more than the specific pick. Biotech rewards patience and diversification and punishes concentration, so beginners are usually better served by breadth than by a single speculative bet.

How is a biotech basket different from a biotech ETF?

An ETF holds a fixed list set by the fund provider, in one ticker, at weights you do not control. A basket is a set of names you choose around a stated thesis, held at target weights you set, so you decide exactly which companies and how much of each. A basket gives you control and a clear thesis; an ETF gives you a hands-off, professionally maintained list. Neither removes biotech’s underlying binary risk.

Walnut is informational and is not an investment adviser. App features, pricing, and availability change; verify current details on each provider's site before deciding. Nothing on this page is a recommendation to buy, sell, or hold any security or to use any particular product.